Inositol Pyrophosphates Determine Exocytotic Capacity

ABSTRACT

The invention provides reagents and methods for treating type II diabetes, as well as methods for identifying compounds for treating type II diabetes.

CROSS REFERENCE

This application is a continuation of U.S. patent application Ser. No. 12/199,388, filed Aug. 27, 2008 which claims priority to U.S. Provisional Patent Application Ser. No. 60/969,443 filed Aug. 31, 2007, incorporated by reference herein in its entirety.

BACKGROUND OF THE INVENTION

Phosphoinositides, in both their water-soluble and lipid forms, have a prominent role in cellular signal-transduction events. Important events are the generation of inositol 1,4,5-trisphosphate (Ins(1, 4, 5)P3) and its regulation of intracellular Ca2+ homeostasis (1) and the 3-phosphorylated inositol lipid products of phosphatidylinositol (PI3 kinase) (2), with diverse roles in mitogenesis, apoptosis and vesicle trafficking Phosphatidylinositol 4,5-bisphosphate (PtdIns (4, 5)P2), the major source of these two signalling systems, is not merely a precursor for the above signal transduction pathways but plays in itself significant roles in vesicle trafficking, exocytosis, cytoskeletal rearrangements and regulation of ion channels (3). In the last decade there has also been a growing appreciation that highly phosphorylated inositol polyphosphates, distant derivatives of the Ins(1, 4, 5)P3 second messenger, play a role in signal-transduction and cellular regulation (4-6). Perhaps the most exciting new vista that has opened concerns the role of diester derivatives of both inositol pentakis- and hexakisphosphates (InsP5 and InsP6). The pyrophosphate derivatives of InsP6 diphosphoinositol pentakisphosphate, and bis-(diphospho)inositol tetrakisphosphate are commonly referred to as ‘InsP7’ and ‘InsP8’. These inositol pyrophosphate derivatives rapidly turnover and are estimated to have similar free energy of hydrolysis as ATP (4). A striking consequence of this high-energy phosphate group is the ability of InsP7 to directly phosphorylate a subset of proteins in an ATP- and enzyme-independent manner (7). The variety of cellular responses, apparently controlled by these molecules (4, 8) may be facilitated by the differential intracellular distribution of the kinases that make them (9). The concentrations of inositol pyrophosphates can be dynamically regulated during key cellular events, underscoring their importance for cell function. For example, InsP7 levels change during cell cycle progression (10) and InsP7 regulates cyclin/CDK complexes (11) whereas InsP8 increases acutely in response to cellular stress (8). However, recent work has also demonstrated a role for InsP6 as an enzymatic co-factor and so by analogy, it is possible that even under non-stimulatory conditions, InsP7 could be an important regulatory molecule.

Phosphoinositides are also key regulators of the insulin secreting pancreatic β-cell (12). These cells are critical players in blood glucose homeostasis and act by coupling increases in the concentration of glucose and other circulatory or neuronal-derived regulators, to the exocytosis of insulin. The highly phosphorylated InsP6 is particularly interesting as it has been shown to activate voltage-dependent L-type Ca2+ channels (13), exocytosis (14, 15) and dynamin-mediated endocytosis (16), all key processes in insulin secretion. A role for InsP7 in the β-cell has not yet been determined. However, given the suggested involvement of inositol pyrophosphates in vesicle trafficking (4), the critical nature of such trafficking events for the process of insulin exocytosis and the high β-cell concentration of InsP6 (13), the immediate precursor of InsP7, we postulated that inositol pyrophosphates may play a significant role in the β-cell. We now demonstrate a novel role for InsP7 in the regulation of insulin exocytosis.

SUMMARY OF THE INVENTION

In one aspect, the present invention provides methods for treating type II diabetes comprising administering to a patient with type II diabetes an effective amount of a therapeutic capable of increasing expression of IP6K1 kinase.

In another aspect, the present invention provides methods for stimulating insulin exocytosis from pancreatic beta cells comprising administering to a patient in need thereof an effective amount of a therapeutic capable of increasing expression IP6KI kinase.

In another aspect, the present invention provides methods for treating type II diabetes comprising administering to a patient with type II diabetes an effective amount of a therapeutic capable of increasing production of InsP₇.

In a further aspect, the present invention provides methods for identifying a compound for treating type II diabetes comprising:

(a) contacting pancreatic beta cells with one or more test compounds; and

(b) determining expression level of IP6K1 kinase and/or levels of InsP7;

wherein an increase in the expression of IP6K1 kinase and/or an increase in InsP7 indicates that the compound is suitable for treating type II diabetes.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1. High basal levels of InsP7 are present in pancreatic β cells and IP6K's are expressed in these cells. (A) Comparison of [3H]-labeled InsP7 as a percentage of [3H]-labeled InsP6 in primary pancreatic islets or insulin secreting MIN6 m9 cells. Data are from 3 separate experiments. (B) The islet data from (A) were transformed to take into account the different B-cell composition of normal (60%) vs. ob/ob (90%), islets. (C). Total RNA was extracted from islets and MIN6m9 cells and reverse transcribed. Relative expression of messenger RNA was measured by quantitative Real time PCR using appropriate primers and probes. Primers and probe for 18S rRNA (TaqMan™ Ribosomal RNA Control Reagents, Applied Biosystems) were used as endogenous control.

FIG. 2. Expression of IP6K's promote exocytosis in pancreatic β-cells. IP6K1 stimulates Ca2+-dependent exocytosis. (A) Individual mouse β-cells were transfected with EGFP (mock) or a combination of EGFP and either a wild-type (IP6K1) or a kinase-dead (IP6K1-K/A) variant of IP6K and subjected to a train of four 500-ms depolarizations using the perforated patch configuration. Increases in cell capacitance (ΔCm) were measured at 3 mM glucose in the extracellular medium. (B) Histogram summarizing the average increase in cell capacitance plotted against the individual depolarizations as well as the total increase in cell capacitance at the end of the train in cells mock transfected or overexpressing either wild-type (IP6K1) or kinase-dead (IP6K1-K/A) IP6K. (C) Histogram showing integrated Ca2+ current (QCa) plotted against the individual depolarizations in cells mock transfected or overexpressing either wild-type or IP6K1-K/A. Values are from 8-12 experiments. *P<0.05. (D) Histogram summarizing the average total increase in cell capacitance at the end of the train in mock transfected cells or cells overexpressing either wild-type (IP6Kn) or kinase-dead (IP6Kn-K/A) type 1, 2 and 3 kinases, respectively. Values are from 7-12 experiments. *P<0.05. (E) INS-1E cells were co-transfected in parallel with pCMV5-hGH and empty vector (pcDNA3) (mock) or with pCMV5-hGH and either wild-type (IP6Kn) or, kinase-dead (IP6Kn-K/A), types 1, 2 and 3 kinases, respectively. hGH secretion was measured in Krebs-Ringer bicarbonate HEPES buffer with 3 mM glucose. hGH release is depicted as secreted hGH in percentage of total hGH. Values from 3 experiments (each in triplicate). *P<0.05.

FIG. 3. InsP7 dose-dependently promotes Ca2+-dependent exocytosis. Individual mouse β-cells were subjected to a train of four 500-ms depolarizations using the standard whole-cell patch configuration. (A) Exocytosis was observed under control conditions and in the presence of 3 μM 5-InsP7 in the pipette-filling solution. 5-InsP7 was allowed to diffuse into the cell for 2 min before initiation of the experiment. (B) Histogram summarizing the average increases in cell capacitance plotted against the individual depolarizations as well as the total increases in cell capacitance at the end of the train in the absence or presence of 3 μM 5-InsP7 in the pipette-filling solution. (C) Histogram showing integrated Ca2+ current (QCa) plotted against the individual depolarizations in the absence or presence of 3 μM InsP7 in the pipette-filling solution. (D) Concentration dependence of stimulatory action of 5-InsP7 on exocytosis evoked by a single membrane depolarization from −70 mV to zero. The curve represents a least-squares fit of the mean data points to the Hill equation. Values are from 5-7 experiments. *P<0.05. (E) A comparison of several isomers of InsP7 at a 10 μM concentration on exocytosis using the same protocols as in (A) above.

FIG. 4. RNA silencing of IP6K1 but not IP6K2 inhibits release of granules from the RRP. (A) Individual mouse β-cells were transfected with siRNA to IP6K1 (No. 1) at 25 nM or a negative control at the same concentration and subjected to a train of four 500-ms depolarizations using the perforated patch configuration. Increases in cell capacitance (ΔCm) were measured at 3 mM glucose in the extracellular medium. (B) Histogram summarizing the average increases in cell capacitance plotted against the individual depolarizations as well as the total increase in cell capacitance at the end of the train in cells mock transfected or overexpressing either siRNA to IP6K1 or negative control. (C) Effect on total capacitance increase following RNA silencing of IP6K1 and IP6K2. (D) Effect of 5-InsP7 on exocytosis in under control conditions and in cells with reduced expression levels of IP6K1.

FIG. 5. Effect of 5-InsP7 on exocytosis is distinct from InsP6. Individual mouse β-cells were subjected to a train of four 500-ms depolarizations using the standard whole-cell patch configuration. Exocytosis was observed under control conditions and in the presence of either 3 μM 5-InsP7 or 10 μM InsP6 in the pipette-filling solution. The inositol phosphates were allowed to diffuse into the cell for 2 min before initiation of the experiment.

FIG. 6. Screening siRNA's in MIN6m9 cells. Six siRNA's for each IP6K were screened for their ability to silence at 100 nM in MIN6m) cells. Two in each case IP6K1 (1 and 4) and IP6K2 (3 and 5) were then used in individually or in combination to silence IP6K1 or IP6K2 respectively. This was compared to 2 negative controls. mRNA was extracted and the expression of the genes quantified using Taqman™ RT-PCR. Data are averages±SEM, n=3)

FIG. 7. RNA silencing of IP6K1 or IP6K2 lowers cellular InsP7 levels. MIN6m9 cells were transfected with selected siRNA for either negative control or IP6K1 and 2. SiRNA's for IP6K1 (1 and 4) were added at 25 nM each. Similar concentrations of the 2 siRNA's for IP6K2 (3 and 5) were added. This was controlled by addition of a 50 nM of a negative control. All 4 siRNA's were also applied simultaneously and controlled with 100 nM negative control siRNA. Two hours after transfection with siRNA medium was changed to a 50 μCi/ml [3H]-inositol containing medium and cells were cultured for 48 h to 72 h. Cells were extracted and subjected to HPLC. Data are expressed relative to total inositol lipid and are means from 3 separate experiments±SEM, n=3).

FIG. 8. Effect of IP6K1-siRNA on single L-type Ca2+ channel activity in MIN6m9 cells. MIN6m9 cells were transfected with selected siRNA for either negative control 50 nM or siRNA's for IP6K1 (1 and 4) at 25 nM each. (A) Examples of single Ca2+ channel currents recorded from cell-attached patches on a control cell (negative control siRNA transfection, left) and a cell subjected to IP6K1-siRNA (right). Both patches contain one L-type Ca2+ channel. (B) Single L-type Ca2+ channel current parameters in control MIN6m9 cells (n=30) and those subjected to IP6K1-siRNA (n=30). There is no significant difference in channel number per patch, open probability, mean closed time and mean open time between control MIN6m9 cells and those subjected to IP6K1-siRNA (P>0.05). Data are presented as means±SEM. Statistical significance was evaluated by either Mann-Whitney U test or unpaired Student's t-test.

DETAILED DESCRIPTION OF THE INVENTION

Within this application, unless otherwise stated, the techniques utilized may be found in any of several well-known references such as: Molecular Cloning: A Laboratory Manual (Sambrook, et al., 1989, Cold Spring Harbor Laboratory Press), Gene Expression Technology (Methods in Enzymology, Vol. 185, edited by D. Goeddel, 1991. Academic Press, San Diego, Calif.), “Guide to Protein Purification” in Methods in Enzymology (M. P. Deutshcer, ed., (1990) Academic Press, Inc.); PCR Protocols: A Guide to Methods and Applications (Innis, et al. 1990. Academic Press, San Diego, Calif.), Culture of Animal Cells: A Manual of Basic Technique, 2^(nd) Ed. (R. I. Freshney. 1987. Liss, Inc. New York, N.Y.), Gene Transfer and Expression Protocols, pp. 109-128, ed. E. J. Murray, The Humana Press Inc., Clifton, N.J.), and the Ambion 1998 Catalog (Ambion, Austin, Tex.).

In one aspect, the present invention provides methods for treating type II diabetes comprising administering to a subject with type II diabetes an amount effective to treat type II diabetes of a therapeutic capable of increasing InsP7 in pancreatic beta cells of the subject.

In a further aspect, the present invention provides methods for treating type II diabetes comprising administering to a subject with type II diabetes an amount effective to treat type II diabetes of a therapeutic capable of increasing expression of IP6K1 kinase in pancreatic beta cells of the subject.

As the inventors have demonstrated in the attached, the pancreatic β-cell maintains high levels of InsP7. This pyrophosphate then serves as an essential player in the insulin secretory process by regulating the readily releasable pool of insulin-containing granules and thereby maintaining the immediate exocytotic capacity of the β-cell. The inventors further showed that endogenous InsP7 generated by IP6K1 is responsible for the enhanced exocytotic capacity in pancreatic beta-cells. Thus, therapeutics capable of increasing expression of IP6K1 kinase can be used to treat type II diabetes by generating InsP7, resulting in increased exocytotic capacity in pancreatic beta cells.

In one embodiment, the therapeutic comprises a gene therapy vector directing expression of IP6K1 or active fragments thereof (Protein accession information: Q 92551 (SEQ ID NO: 1); cDNA accession information (Alternative splice variants) 1. NM_(—)153273.3 (SEQ ID NO: 3), 2. NM_(—)001006115 (SEQ ID NO: 2)) comprises a gene therapy vector directing expression of IP6K1 or active fragments thereof. The gene therapy method comprises administration of a nucleic acid construct capable of expressing IP6K1 or active fragments thereof in the subject, and preferably in pancreatic beta cells of the subject. In one example, the cDNA sequences may be operably linked with an insulin promoter (Leibiger, Mol. Cell. 1:933-938 (1998)). Such gene therapy and delivery techniques are known in the art; see, for example, WO90/11092, which is herein incorporated by reference, or: M. I. Phillips (Ed.): Gene Therapy Methods. Methods in Enzymology, Vol. 346, Academic Press, San Diego 2002. Thus, for example, cells from the subject may be engineered ex vivo with a nucleic acid construct comprising a promoter operably linked to the nucleic acid molecule corresponding to the molecule to be introduced, with the engineered cells then being provided to the subject to be treated. Such methods are well-known in the art. For example, see Belidegrun, A., et al., J. Natl. Cancer Inst. 85: 207-216 (1993); Ferrantini, M. et al., Cancer Research 53: 1107-1112 (1993); Ferrantini, M. et al., J. Immunology 153: 4604-4615 (1994); Kaido, T., et al., Int. J. Cancer 60: 221-229 (1995); Ogura, H., et al., Cancer Research 50: 5102-5106 (1990); Santodonato, L., et al., Human Gene Therapy 7:1-10 (1996); Santodonato, L., et al., Gene Therapy 4:1246-1255 (1997); and Zhang, J.-F. et al., Cancer Gene Therapy 3: 31-38 (1996)), which are herein incorporated by reference. The cells which are engineered may be, for example, pancreatic beta cells.

The nucleic acid molecules may also be delivered as a naked nucleic acid molecule. The term “naked” nucleic acid molecule refers to sequences that are free from any delivery vehicle that acts to assist, promote or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the nucleic acid molecules used in gene therapy can also be delivered in liposome formulations and lipofectin formulations and the like that can be prepared by methods well known to those skilled in the art. Such methods are described, for example, in U.S. Pat. Nos. 5,593,972, 5,589,466, and 5,580,859, which are herein incorporated by reference.

The naked nucleic acid molecules are delivered by any method known in the art, including, but not limited to, direct needle injection at the delivery site, intravenous injection, topical administration, catheter infusion, and so-called “gene guns”. These delivery methods are known in the art. The constructs may also be delivered with delivery vehicles such as viral sequences, viral particles, liposome formulations, lipofectin, precipitating agents, etc.

In another embodiment, the therapeutic comprises IP6K1 or active fragments thereof. The polypeptides can be administered via any suitable technique, including but not limited to delivery as a conjugate with a transduction domain, which are one or more amino acid sequence or any other molecule that can carry an active domain across cell membranes. These domains can be linked to other polypeptides to direct movement of the linked polypeptide across cell membranes. (See, for example, Cell 55: 1179-1188, 1988; Cell 55: 1189-1193, 1988; Proc Natl Acad Sci USA 91: 664-668, 1994; Science 285: 1569-1572, 1999; J Biol Chem 276: 3254-3261, 2001; and Cancer Res 61: 474-477, 2001)

In a further aspect, the present invention provides methods for identifying a compound for treating type II diabetes comprising:

(a) contacting pancreatic beta cells with one or more test compounds; and

(b) determining expression level of IP6K1 kinase and/or levels of InsP7;

wherein an increase in the expression of IP6K1 kinase and/or an increase in InsP7 indicates that the compound is suitable for treating type II diabetes.

As noted above, therapeutics capable of increasing expression of IP6K1 kinase can be used to treat type II diabetes by generating InsP7, resulting in increased exocytotic capacity in pancreatic beta cells. Thus, compounds that can be used to increase expression of IP6K1 kinase and/or InsP7 in pancreatic beta cells can be used to treat type II diabetes.

Determining expression levels of IP6K1 kinase and/or an increase in InsP7 in the pancreatic beta cells can be performed using any technique in the art, including but not limited to those disclosed in the examples that follow.

As used herein, “basal glucose conditions” mean a glucose concentration of between 1 and 6 mM glucose; in one embodiment, 3 mM glucose is used. As is understood by those of skill in the art, basal glucose concentration may vary between species. Basal glucose concentration can be determined for any particular cell or tissue type by those conditions that do not induce changes in, for example, cytoplasmic free Ca2+ concentration or insulin release.

As used herein, “pancreatic β cells” are any population of cells that contains pancreatic β islet cells. The cells can be obtained from any mammalian species, or may be present within the mammalian species when the assays are conducted in vivo. Such pancreatic β islet cell populations include the pancreas, isolated pancreatic islets of Langerhans (“pancreatic islets”), isolated pancreatic β islet cells, and insulin secreting cell lines. Methods for pancreatic isolation are well known in the art, and methods for isolating pancreatic islets, can be found, for example, in Cejvan et al., Diabetes 52:1176-1181 (2003); Zambre et al., Biochem. Pharmacol. 57:1159-1164 (1999), and Fagan et al., Surgery 124:254-259 (1998), and references cited therein. Insulin secreting cell lines are available from the American Tissue Culture Collection (“ATCC”) (Rockville, Md.). In a further embodiment where pancreatic β cells are used, they are obtained from ob/ob mice, which contain more than 95% β cells in their islets.

In order to derive optimal information on the ability of the one or more test compounds to increase in the expression of IP6K1 kinase and/or an increase in InsP7 in pancreatic beta cells, it is preferred to compare IP6K1 kinase and/or InsP7 levels ion experimental cells with levels from control cells. Such control cells can include one or more of the following:

1. The same host cells, treated in the same way except not contacted with the one or more test compounds;

2. The same host cells, treated in the same way except contacted with the one or more test compounds at different time points (for analyzing time-dependent effects); and

3. The same host cells, treated in the same way except contacted with different concentrations of the one or more test compounds (for analyzing concentration-dependent effects);

When the test compounds comprise polypeptide sequences, such polypeptides may be chemically synthesized or recombinantly expressed. Recombinant expression can be accomplished using standard methods in the art, as disclosed above. Such expression vectors can comprise bacterial or viral expression vectors, and such host cells can be prokaryotic or eukaryotic. Synthetic polypeptides, prepared using the well-known techniques of solid phase, liquid phase, or peptide condensation techniques, or any combination thereof, can include natural and unnatural amino acids. Amino acids used for peptide synthesis may be standard Boc (Nα-amino protected Nα-t-butyloxycarbonyl) amino acid resin with standard deprotecting, neutralization, coupling and wash protocols, or standard base-labile Nα-amino protected 9-fluorenylmethoxycarbonyl (Fmoc) amino acids. Both Fmoc and Boc Nα-amino protected amino acids can be obtained from Sigma, Cambridge Research Biochemical, or other chemical companies familiar to those skilled in the art. In addition, the polypeptides can be synthesized with other Nα-protecting groups that are familiar to those skilled in this art. Solid phase peptide synthesis may be accomplished by techniques familiar to those in the art and provided, such as by using automated synthesizers.

When the test compounds comprise antibodies, such antibodies can be polyclonal or monoclonal. The antibodies can be humanized, fully human, or murine forms of the antibodies. Such antibodies can be made by well-known methods, such as described in Harlow and Lane, Antibodies; A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., (1988).

When the test compounds comprise nucleic acid sequences, such nucleic acids may be chemically synthesized or recombinantly expressed as well. Recombinant expression techniques are well known to those in the art (See, for example, Sambrook, et al., 1989, supra). The nucleic acids may be DNA or RNA, and may be single stranded or double. Similarly, such nucleic acids can be chemically or enzymatically synthesized by manual or automated reactions, using standard techniques in the art. If synthesized chemically or by in vitro enzymatic synthesis, the nucleic acid may be purified prior to introduction into the cell. For example, the nucleic acids can be purified from a mixture by extraction with a solvent or resin, precipitation, electrophoresis, chromatography, or a combination thereof. Alternatively, the nucleic acids may be used with no or a minimum of purification to avoid losses due to sample processing.

When the test compounds comprise compounds other then polypeptides, antibodies, or nucleic acids, such compounds can be made by any of the variety of methods in the art for conducting organic chemical synthesis.

Test compounds identified as increasing the expression of IP6K1 kinase and/or an increase in InsP7 in the pancreatic beta cells can be further assessed for use as a candidate compound for treating type II diabetes using any further technique, including but not limited to contacting pancreatic beta cells with the test compounds and measuring insulin release induced by the test compounds, and/or by measuring resulting pancreatic beta cell capacitance induced by the test compounds; those compounds that increase insulin release and/or capacitance (which is a measure of insulin exocytosis as described below) compared to control may be of particular value as candidate compounds for treating type II diabetes. In a further embodiment, measuring capacitance is performed as described below, and those test compounds that elicit an exocytotic response at the first depolarization are considered good candidate compounds for treating type II diabetes.

EXAMPLES Materials and Methods

Reagents and constructs. 5-Diphosphoinositol pentakisphosphate (InsP7) was synthesized as described previously (25). The ORF for IP6K1, IP6K2 and IP6K3, were obtained by digestion using SalI-NotI pCMV-IP6K1, pCMV-IP6K2 (26) and by digestion using SalI pGST-IP6K3 (27). The purified ORF were subcloned in the eukaryotic expression vector pCMV-Myc (Clontech). Kinase-dead versions were prepared as follows. Previous studies have identified a lysine in InsP3KA that is critical for catalytic activity (28). In mouse IP6K1, human IP6K2 and human IP6K3 this lysine occurs at position 226, 222 and 217, respectively. For IP6K1 we mutated lysine 226 to alanine using the following oligo: K26A, 5′-GTGTGCTGGACTTGGCCATGGGTACCCG-3′ (SEQ ID NO: 4) and complement. For IP6K2 we mutated lysine 222 to alanine using the following oligo: K222A, 5′-GTCCTTGACCTCGCGATGGGCACACGA-3′ (SEQ ID NO: 5) and complement. For IP6K3 we mutated lysine 217 to alanine using the following oligo: K217A, 5′-CCCTGTGTCCTGGATCTGGCCATGGGGACCCGGCAGCAC-3′ (SEQ ID NO: 6) and complement.

Constructs were tested in INS-1E cells to establish their efficacy. IP6K1-3 and their respective catalytically inactive forms were transfected into INS-1E cells (protocols below). All constructs were expressed at similar level, as judged by western blotting. Moreover, IP6K1-3 wt, but not their catalytically inactive forms (K/A) increased cellular InsP7 up to 6-fold.

RNAi's were obtained from Ambion Inc (Austin, Tex.) and the following RNAi ID's were used to silence IP6K's. RNAi's to IP6K1 (1, siRNAi ID=188560) and (4, siRNAi ID=71758). RNAi's for IP6K2 (3, siRNA ID=287702) and (5, siRNA ID=292211). Non-targeting controls (1, siRNA ID 4611) and (2, siRNA ID=4613) were used as negative controls. These siRNA's were also supplied by Ambion with Cy3 fluorescent tags and used in the primary mouse beta cell experiments.

RNA Extraction and Real Time-PCR.

Total RNAs were extracted from cells using the RNeasy™ Micro Kit (Qiagen Inc, Valencia, Calif.). The RNAs were digested with DNase I for 1 hour at 37° C. (Fermentas, St. Leon Rot, Germany) and then re-purified with RNeasy™ Micro Kit (Qiagen Inc). The Applied Biosystem MultiScribe™ Reverse Transcriptase kit was used to reverse transcribe 1 μg of purified RNA according to manufacture's instructions. 3.94 μl of the resulting cDNAs from the reverse transcriptase reaction were diluted in 10.06 μl sterile water and 1.25 μl aliquots of each sample were tested in triplicate for each different quantitative PCR reaction. Relative expression of messenger RNA was measured by quantitative RT-PCR (with TaqMan Gene Expression Assays products on an ABI PRISM™ 7700 Sequence Detection System, Applied Biosystems, Foster City, Calif.). For the analysis, the following TaqMan™ assays (Applied Biosystems) were used: for IP6K1: inositol hexaphosphate kinase 1, for IP6K2: inositol hexaphosphate kinase 2 and for IP6K3: inositol hexaphosphate kinase 3. Primers and probe for 18S rRNA (TaqMan™ Ribosomal RNA Control Reagents, Applied Biosystems) were used as endogenous control.

Cell Culture and Transfection.

HIT T15 cells and mouse islets were maintained in RPMI-1640 medium as described previously (29). Labeling was undertaken with [3H] myo-inositol (GE Healthcare, Amersham Biosciences, Uppsala, Sweden) 10 or 50 μCi/ml for insulin-secreting HIT T15 cells and islets respectively in a special RPMI-1640 medium, described previously (29). Cells were labeled for 72 h and labeling from 48-168 h did not change the InsP6 to InsP7 ratio. For experiments, islets or cells were transferred with washing into a Krebs buffer and incubated for 30 min under basal glucose conditions (0.1 mM for cell lines and 3 mM for islets). Inositol polyphosphates were extracted and separated on HPLC as described previously (29). INS-1E cells were cultured as described elsewhere (30). Mouse pancreatic islets were isolated from female NMRI mice (Bomholtgaard, Ry, Denmark) or normo-glycemic ob/ob mice as previously described (31, 32). Cells were incubated in RPMI 1640 medium (Invitrogen Corporation, Carlsbad, Calif.) supplemented with 10% (v/v) heat-inactivated fetal calf serum, 100 IU/ml penicillin and 100 μg/ml streptomycin. Single mouse islet cells were transfected adherently the day after plating with pIRES2-EGFP (mock) or a combination of pIRES2-EGFP and construct of interest at 2 μg/ml in the above RPMI 1640 cell culture medium using Lipofectamine™ 2000 (Invitrogen Corporation, Carlsbad, Calif.) according to manufacture's instructions. Lipofectamine™ was used in a ratio of 4:1 to DNA. Cells were used 48 h after transfection. Based on GFP fluorescence, the transfection efficiency in mouse islet cells amounted to 8+/−1% (n=124 cells; 4 different cell preparations and transfections). SiRNA's were tranfected into MIN6m9 cells and primary islet cells using Lipofectamine™ 2000 and Opti.MEM™ media. The medium was changed the following day into normal culture media for either MIN6m9 cells or primary islet cells and the cells cultured for a further 4 days.

Capacitance Measurements.

Cells expressing EGFP were selected for capacitance measurements. Exocytosis was monitored as changes in cell capacitance using either the perforated patch or standard whole-cell configuration of the patch-clamp technique and an EPC9 patch-clamp amplifier (Heka Elektronik, Lambrecht/Pfalz, Germany). The pipette solution for the perforated patch configuration consisted of (in mM) 76 Cs2SO4, 10 NaCl, 10 KCl, 1 MgCl2, 5 HEPES (pH 7.35 with CsOH) and 0.24 mg/ml amphotericin B. Perforation required a few minutes, and the voltage clamp was considered satisfactory when the Gseries (series conductance) was stable and >35 nS. The pipette solution used for standard whole-cell recordings contained (in mM) 125 Cs-glutamate, 10 CsCl, 10 NaCl, 1 MgCl2, 5 HEPES, 0.05 EGTA, 0.01 GTP and 3 MgATP (pH 7.15 using CsOH). InsP7 isomers were dissolved in the pipette-filling solution to the final concentrations indicated in the text and kept on ice until use. The extracellular medium was composed of (in mM) 118 NaCl, 20 tetraethylammonium-Cl, 5.6 KCl, 1.2 MgCl2, 2.6 CaCl2, 5 HEPES (pH 7.40 using NaOH) and 3 glucose. The stimulation protocol consisted of trains of four 500-ms depolarizations applied at 1 Hz and went from −70 mV to zero mV. The capacitance measurements were performed at 33° C. and the recording chamber was perfused at a rate of 1.5 ml/min.

Measurement of Single L-Type Ca2+ Channel Activity

Cell-attached patch recordings were performed in control MIN6m9 cells and those subjected to IP6K1-siRNA as described previously (32). Briefly, typical electrode resistance was 2-4 MΩ. Cell-attached single-channel recordings were made with Ba2+ as the charge carrier (in mM): 110 BaCl2, 10 TEA-Cl, 5 HEPES-Ba(OH)2 and pH 7.4 and a depolarizing external recording solution, containing (in mM) 125 KCl, 30 KOH, 10 EGTA, 2 CaCl2, 1 MgCl2, 5 HEPES-KOH and pH 7.15, is used to bring the intracellular potential to ˜0 mV. Recordings are made with an Axopatch™ 200 amplifier (Axon Instruments, Foster City, Calif.). Voltage pulses (200 ms) are applied at a frequency of 0.5 Hz to depolarize cells from a holding potential of −70 mV to a membrane potential of 0 mV. Resulting currents are filtered at 1 kHz, digitized at 5 kHz and analyzed with the software program pCLAMP™ 6 (Axon Instruments, Foster City, Calif., U.S.A.).

Human Growth Hormone (hGH) Release Assay.

After transfection with pCMV5-hGH and either empty vector pcDNA3 or plasmid of interest, INS-1E cells were seeded into 48-multiwell plates (2×10⁵ cells per well) and cultured for 48 h. Incubation and secretion experiments were performed as described (33) using the same extracellular medium as described above and supplemented with 3 mM glucose. hGH levels in the various samples were measured using ELISA (Roche, Mannheim, Germany).

Statistical analysis. Results are presented as mean values±S.E.M. for indicated number of experiments. Statistical significances were evaluated using Dunnett's test for multiple comparisons to a control and Tukey's test when multiple comparisons between groups were required.

Results

Using [3H] myo-inositol labelling protocols we examined insulin-secreting cells and pancreatic islets for the presence of inositol pyrophosphate species. InsP7 was identified by its co-elution with a bone fide InsP7 standard generated using InsP6 kinase (data not shown). Very little InsP8 was detectable. FIG. 1A shows InsP7 levels expressed as a percentage of cellular InsP6 levels for an insulin-secreting cell line or primary β-cells. In normal mouse pancreatic islets (60% β-cells), the relative level of InsP7 is about 5% of the InsP6 level. In contrast, the percentage of InsP7 in islets from ob/ob mice, which have more than about 90% β-cells, is about 8%. This suggests that the elevated InsP7 levels are restricted to the -cells. Normalizing the primary mouse data to 100% β-cells (FIG. 1B) suggests that they maintain InsP7 levels at about 9% of the InsP6 concentration. Of the insulin secreting cell lines, only HIT-T15 cells have a similar level of InsP7 (10% of InsP6). Using the equilibrium labelling techniques (13) which can only be reliably applied to growing, cultured cells, we were able to estimate the basal concentration of InsP7 in HIT-T15 cells to be 5.8+/−0.14 μM, (±SEM, n=3), reflecting a concentration at the top end of the range that has been estimated in other mammalian cells or yeast (1-5 μM) (4). Since InsP7 is in a state of rapid exchange with the cellular InsP6 pool in β-cells (data not shown) in common with other mammalian cells (4) and the cellular concentration of InsP6 in β-cells is also high (13), it is perhaps not surprising that high levels of InsP7 exist in these cells.

An important caveat is that the high InsP7 is a cell-wide average which doesn't take into account separate cellular compartments. This is particularly important as one of the main isoforms of InsP6 kinase, IP6K2, can be nuclear (9) and thus the InsP7 it produces may not influence events in the cytosol or plasma membrane, for example vesicle trafficking or exocytosis, respectively. Therefore, using Taqman™-based quantitative Real time PCR we examined islet and β-cell lysates for the presence of IP6K isoforms. FIG. 1C demonstrates the expression of IP6K1 and IP6K2, but not IP6K3. Expression levels for the two kinases were similar in a given cell type, however, the expression of IP6K1 and 2 was lower in the primary cells compared to the cell line MIN6, perhaps reflecting the fact that InsP7 metabolism is up-regulated during the cell cycle (10, 11). Thus the high InsP7 levels are not likely to reflect an exclusive nuclear pool but are likely to be consistently high throughout the cell and thus could influence insulin secretion.

To investigate whether high InsP7 concentrations are responsible for keeping β-cells in a responsive state, we over-expressed all 3 reported mammalian IP6K's in primary β-cells under basal conditions and examined whether stimulated exocytosis was subsequently enhanced. We used increases in cell capacitance as a measure of exocytosis. This technique detects the increase in β-cell surface area that occurs when the insulin-containing granules fuse with the plasma membrane (17). The perforated patch whole-cell technique was used to allow measurements in metabolically intact cells and exocytosis was elicited by trains consistent of four 500-ms depolarizing pulses from −70 mV to 0 mV. In mock transfected cells, the capacitance increase elicited by the train amounted to 79+/−11 fF (n=8; FIG. 2A, B). In cells overexpressing IP6K1 the amplitude of the capacitance increase was stimulated by 153% and averaged 198+/−12 fF (P<0.05; n=10), whereas no effect on exocytosis was observed in cells overexpressing a kinase-dead version of IP6K1 (FIG. 2A, B). Interestingly, the capacitance increase evoked by the first depolarization was augmented by 293% in cells overexpressing wild-type IP6K1. Exocytosis during the first depolarization is believed to largely represent the content of the readily releasable pool (RRP) (18). The size of the RRP (in fF) can be estimated using the equation: RRP=S/(1−R2), where S is the sum of the response to the first (ΔC1) and the second (ΔC2) pulse and R is the ratio ΔC2/ΔC1 (18). We estimate that the RRP averaged 96+/−9 fF (n=8) and 225+/−21 fF (n=10) in mock and wildtype IP6K1 transfected cells, respectively. Thus, IP6K1 increased the size of the RRP by 134%. Using a conversion factor of 3 fF per granule (19), it can be estimated that the RRP contains 30 and 75 granules in mock and wildtype IP6K1 transfected cells, respectively. The stimulatory action of IP6K1 is restricted to the first depolarization and little enhancement is seen during the final three pulses (FIG. 2B). The exhaustion of the exocytotic response during the train is unlikely to reflect inactivation of the Ca2+ current with resulting suppression of Ca2+-induced exocytosis (FIG. 2C).

FIG. 2D shows that the ability of wild-type IP6K1 to stimulate exocytosis is shared by IP6K2 and IP6K3. Overexpression of a kinase-dead version of IP6K 2 and IP6K3 did not affect the exocytotic capacity compared to mock transfected cells (FIG. 2D). To confirm a role of IP6K's in the control of exocytosis, we tested the effect of their overexpression in INS-1E cells using the hGH transient co-transfection assay, in which hGH acts as a reporter of exocytosis from transfected cells only. INS-1E cells represent a suitable cell system since total increases in cell capacitance in cells overexpressing IP6K1 were comparable to those observed in primary mouse β cells (data not shown). Overexpression of IP6K1-3 stimulated hGH secretion 150% above basal (P<0.05; n=9-12), an effect that was not shared by their kinase-dead mutants. (FIG. 2E). Based on the fact that only IP6K1 and 2 are present in β-cells, these and not IP6K3 are likely modulators of exocytosis.

An important concern is that IP6K's can also use InsP5 as a substrate, generating a different subset of inositol pyrophosphates (4). Therefore, it was necessary to verify that InsP7 is able to directly promote exocytosis. The mammalian InsP7 is the 5-isomer and this was used in detailed experiments (FIG. 3A-D). We also assessed other theoretical isomers of InsP7 (FIG. 3E). To measure the effects of 5-InsP7 on exocytosis, we applied trains of depolarizations in standard whole-cell experiments where the β-cell was dialyzed with a solution containing 3 μM InsP7. Following establishment of the whole-cell configuration, the cell was allowed two minutes equilibration period. A train consisting of four 500 ms depolarizations from −70 mV to 0 mV was then applied to evoke exocytosis. In a series of six experiments, the total increase in cell capacitance amounted to 231+/−12 fF (P<0.01) in the presence of 3 μM InsP7 in the pipette-filling solution and 77+/−11 fF under control conditions, respectively (FIG. 3A). As was the case for cells overexpressing IP6K1-3 the capacitance increase evoked by the first depolarization in the presence of 5-InsP7 was strongly stimulated with only little effect on exocytosis in response to the subsequent 3 depolarizations (FIG. 3B). The ability of 5-InsP7 to stimulate exocytosis was not associated with a change in the whole-cell Ca2+ current (FIG. 3C). The stimulatory action of 5-InsP7 on exocytosis was concentration dependent (FIG. 3D). No stimulation of exocytosis was observed at ≦0.1 μM InsP7. At higher concentrations, 5-InsP7 stimulated exocytosis by 90-410%. Approximating the average data points to the Hill equation yielded a half-maximal stimulatory effect of 1.02 μM and a co-operativity factor of 1.5. Maximal stimulation of exocytosis was observed at concentrations of InsP7≧10 μM, which produced >380% stimulation (FIG. 4D). Thus, 5-InsP7 dose-dependently enhances exocytosis within the physiological range of InsP7 concentrations (1-10 μM). Other isomers of InsP7 were also able to stimulate exocytosis at 10 μM, however CH-PP, a simple pyrophosphate based on cyclohexane, was ineffective (FIG. 4E). Under the conditions used to examine InsP7's effect on exocytosis, the net effect of InsP6 was to promote endocytosis not exocytosis (see FIG. 5). This is because the effect of InsP6 on exocytosis can only be discerned under conditions in which endocytosis is inhibited (15). This is not the case for InsP7. Furthermore, the effect of InsP6 on exocytosis, when endocytosis is inhibited, does not selectively promote secretion from the RRP (data not shown). Our data illustrate that InsP7 and InsP6 have distinct effects on exocytosis. These experiments and those involved in overexpression of kinases do not preclude a role for a more phosphorylated pyrophosphate i.e. InsP8, however since this pyrophosphate is either at a very low concentration or undetectable in β-cells (data not shown), it is unlikely to play a physiological role.

All our data to this point indicate a role for InsP7 in regulated exocytosis, however our results are based on exogenous addition of either enzymes or InsP7. To test whether endogenous InsP7 contributes to the exocytotic capacity in a physiologically relevant manner, we silenced IP6K1 and IP6K2 in -cells using siRNA. Mouse-specific siRNA's were screened using the mouse-cell line, MIN6 and Taqman™ Real time PCR gene expression assays (see FIG. 6). Elimination of either IP6K1 or IP6K2 significantly reduced cellular InsP7 levels (see FIG. 7). Suitable siRNA candidates were fluorescently tagged and transfected into primary β-cells. Cell capacitance measurements on fluorescent cells using the perforated patch technique described above were carried out. Interestingly, only the silencing of IP6K1 but not IP6K2 (FIG. 4C) inhibited the exocytotic capacity, and the effect of silencing was again most pronounced on the first pulse reflecting depletion of the RRP of granules (FIGS. 4A,B). Furthermore, addition of 5-InsP7 in the whole cell mode when the IP6K1 had been silenced was able to restore normal exocytotic response (FIG. 4D). Thus endogenous InsP7 generated by IP6K1 but not IP6K2 is responsible for the enhanced exocytotic capacity in pancreatic-cells. The discrepancy between our exogenous vs. endogenous systems may reflect a differential distribution or cellular associations of the 2 kinases in vivo. Indeed IP6K1 can associate with proteins involved in exocytosis which IP6K2 cannot (20). Interestingly, other studies looking at the role of IP6K2 in apoptosis indicate a similar pattern (21). That is, substantial overexpression of IP6K1-3 leads to an increase in apoptosis, however only the silencing of IP6K2 prevents it. In both cases the supra physiological increase of InsP7 clearly overcomes some compartmentalization exhibited by the different kinases.

One possible mechanistic explanation for the effect of 5-InsP7 on exocytosis may be direct stimulation of voltage-gated L-type Ca2+ channel activity, as previously shown for InsP6 (13). Although the whole-cell Ca2+ channel data speak against this (FIGS. 2C and 3C), a detailed analysis was made applying the cell-attached patch configuration, maintaining an intact intracellular milieu, in MIN6m9 cells subjected to IP6K1-siRNA, which significantly decreases intracellular InsP7 (FIG. 7). As shown in FIG. 8, IP6K1 siRNA did not significantly alter channel number per patch, open probability, mean closed time and mean open time (P>0.05). Hence, InsP7 does not affect L-type Ca2+ channel activity, which in striking contrast to InsP6 (13).

In summary, the pancreatic β-cell maintains high levels of InsP7. This pyrophosphate then serves as an essential player in the insulin secretory process by regulating the readily releasable pool of insulin-containing granules and thereby maintaining the immediate exocytotic capacity of the β-cell. An important question for the future is whether disruption of InsP7 metabolism plays any role in the pathogenesis of type 2 diabetes, a disease characterized by a secretory defect in the pancreatic β-cell (22). In this respect, hints are provided by the putative disruption of the IP6K1 gene in a Japanese family with type 2 Diabetes (23) and the reduction of both plasma insulin levels and glucose tolerance in mice in which the IP6K1 gene has been deleted (24).

REFERENCES

-   1. M. J. Berridge, Ann N Y Acad Sci. 766, 31 (1995). -   2. B. Vanhaesebroeck et al., Annu Rev Biochem. 70, 535 (2001). -   3. T. Takenawa, T. Itoh, Biochim Biophys Acta. 1533, 190 (2001). -   4. M. Bennett, S. M. Onnebo, C. Azevedo, A. Saiardi, Cell Mol Life     Sci. 63, 552 (2006). -   5. R. F. Irvine, M. J. Schell, Nat Rev Mol Cell Biol. 2, 327 (2001). -   6. S. B. Shears, Biochem J. 377, 265 (2004). -   7. A. Saiardi, R. Bhandari, A. C. Resnick, A. M. Snowman, S. H.     Snyder, Science. 306, 2101 (2004). -   8. X. Pesesse, K. Choi, T. Zhang, S. B. Shears, J Biol Chem. 279,     43378 (2004). -   9. A. Saiardi, E. Nagata, H. R. Luo, A. M. Snowman, S. H. Snyder, J     Biol Chem. 276, 39179 (2001). -   10. C. J. Barker, J. Wright, P. J. Hughes, C. J. Kirk, R. H.     Michell, Biochem J. 380, 465 (2004). -   11. Y. S. Lee, S. Mulugu, J. D. York, E. K. O'Shea, Science 316 109     (2007). -   12. C. J. Barker, I. B. Leibiger, B. Leibiger, P.-O. Berggren, Am J     Physiol Endocrinol Metab. 283, E1113 (2002). -   13. O Larsson et al., Science. 278, 471 (1997). -   14. A. M. Efanov, S. V. Zaitsev, P.-O. Berggren, Proc Natl Acad Sci     USA. 94, 4435 (1997). -   15. M. Høy, P.-O. Berggren, J. Gromada, J Biol Chem. 278, 35168     (2003). -   16. M. Høy. et al., Proc Natl Acad Sci USA. 99, 6773 (2002). -   17. P. Rorsman P, E. Renstrom Diabetologia. 46, 1029 (2003). -   18. K. D. Gillis, R. Mossner, E. Neher, Neuron 16, 1209 (1996). -   19. C. S. Olofsson. et al., Pflügers Archiv 444, 43 (2002).

20. H. R. Luo et al., Neuron. 31, 439 (2001).

-   21. E. Nagata et al. J Biol Chem. 280, 1634-40 (2005) -   22. P. Marchetti, S. Del Prato, R. Lupi, S. Del Guerra, Nutr Metab     Cardiovasc Dis. 16 Suppl 1:S3 (2006). -   23. J. Kamimura et al., J Hum Genet. 49, 360 (2004). -   24. J. T. Lexicon Knockout Mouse NIH-0750, Mouse Genome Database     (MGD), Mouse Genome Informatics Web Site,     informatics.jax.org/external/ko/lexicon/1223.html (18 Jul. 2006). -   25. K. M. Reddy, K. K. Reddy, J. R. Falck, Tetrahedron Letters 38,     4951 (1997) -   26. A. Saiardi, H. Erdjument-Bromage, A. M. Snowman, P.     Tempst, S. H. Snyder, Curr. Biol. 9, 1323 (1999). -   27. A. Saiardi, E. Nagata, H. R. Luo, A. M. Snowman, S. H. Snyder, J     Biol Chem. 276, 39179 (2001). -   28. S. Togashi, K. Takazawa, T. Endo, C. Erneux, T. Onaya,     Biochem. J. 326, 221 (1997). -   29. O. Larsson et al., Science. 278, 471 (1997). -   30. A. Merglen et al., Endocrinology 145, 667 (2004). -   31. M. Høy et al., Proc Natl Acad Sci USA. 99, 6773 (2002). -   32. J. Yu et al., J. Biol. Chem. 278, 46210 (2003). -   33. L. Lilja et al., J. Biol. Chem. 279, 29534 (2004). 

1. A method for treating type II diabetes comprising administering to a patient with type II diabetes an effective amount of a therapeutic capable of increasing expression of IP6K1 kinase.
 2. The method of claim 1, wherein the increased expression of IP6K1 results in an increase in InsP₇ expression.
 3. A method for stimulating insulin exocytosis from pancreatic beta cells comprising administering to a patient in need thereof an effective amount of a therapeutic capable of increasing expression IP6KI kinase.
 4. The method of claim 3, wherein the increased expression of IP6K1 results in an increase in InsP₇ expression.
 5. The method of claim 1 wherein the therapeutic comprises a gene therapy vector capable of increasing the expression of IP6K1.
 6. The method of claim 1 wherein the therapeutic comprises IP6K1, or an active fragment thereof.
 7. A method for treating type II diabetes comprising administering to a patient with type II diabetes an effective amount of a therapeutic capable of increasing production of InsP₇.
 8. A method for identifying a compound for treating type II diabetes comprising: (a) contacting pancreatic beta cells with one or more test compounds; and (b) determining expression level of IP6K1 kinase and/or levels of InsP7; wherein an increase in the expression of IP6K1 kinase and/or an increase in InsP7 indicates that the compound is suitable for treating type II diabetes. 